Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 13, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 18, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001628280-26-009282
Filed / recorded
Feb 18, 2026, 10:43 PM UTC
Added to OQRO
Oct 8, 2026, 12:30 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ADC Therapeutics SA
Issuer CIK
1771910
Ticker
ADCT
Reporting person
Mohamed Zaki
Relationship
Officer
Officer title
Chief Medical Officer
Security
Common Shares
Table
Non-derivative (Table I)
Transaction date
Feb 13, 2026
Transaction code
A
Shares / units
285,200
Price per share
$3.99
Acquired / disposed
Acquired (A)
Shares owned after
707,020
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.